Inflammatory Bowel Disease

 

 Buy Article Permissions and Reprints

The pathogenesis of inflammatory bowel disease (IBD) continues to be explored, with the emphasis on genetically determined host immune dysregulation as it applies to interactions with luminal bacteria. The role of endoscopic ultrasound in the evaluation of IBD continues to be studied. Recent advances in the evaluation of enterocutaneous fistulas have been made through the use of hydrogen peroxide to enhance definition of the fistula course and characteristics of the neighboring bowel, as evaluated by transabdominal ultrasound. Refinements have been made in the use and interpretation of the results of surveillance colonoscopy for detection of colorectal cancer and dysplasia in IBD, but a consistent approach still needs to be applied by individual practitioners. New data exist on the usefulness of methotrexate for maintenance of remission, while a lack of efficacy has been demonstrated for mesalamine in the prevention of postoperative recurrence. The role of anti-tumor necrosis factor (TNF) antibody therapy in the treatment of IBD continues to be investigated.

References

• 1 Marteau P. Inflammatory bowel disease.  Endoscopy. 2000;  32 131-137
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Orholm M, Fonager K, Sorensen H. Risk of ulcerative colitis and Crohn's disease among offspring of patients with chronic inflammatory bowel disease.  Am J Gastroenterol. 1999;  94 3236-3238
  CrossrefPubMedGoogle Scholar
• 3 McCartney S, Mitchell J, Fairclough P, et al. Selective COX-2 inhibitors and human inflammatory bowel disease.  Aliment Pharmacol Ther. 1999;  13 1115-1117
  CrossrefPubMedGoogle Scholar
• 4 Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans.  Gut. 1999;  44 812-818
  PubMedGoogle Scholar
• 5 Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the fecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.  Aliment Pharmacol Ther. 1999;  13 1103-1108
  PubMedGoogle Scholar
• 6 Rembacken B, Snelling A, Hawkey P, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial.  Lancet. 1999;  354 635-639
  CrossrefPubMedGoogle Scholar
• 7 Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale?.  Inflamm Bowel Dis. 2000;  6 107-115
  PubMedGoogle Scholar
• 8 Bernstein C, Blanchard J. Viruses and inflammatory bowel disease: is there evidence for a causal relationship?.  Inflamm Bowel Dis. 2000;  6 34-39
  PubMedGoogle Scholar
• 9 Kawashima H, Mori T, Kashiwagi Y, et al. Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism.  Dig Dis Sci. 2000;  45 723-729
  CrossrefPubMedGoogle Scholar
• 10 Pardi D, Tremaine W, Sandborn W, et al. Early measles virus infection is associated with the development of inflammatory bowel disease.  Am J Gastroenterol. 2000;  95 1480-1485
  CrossrefPubMedGoogle Scholar
• 11 Korzenik J, Diekgraefe B. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease.  Dig Dis Sci. 2000;  45 1121-1129
  CrossrefPubMedGoogle Scholar
• 12 Cucchiara S, Celentano L, de Magistris T, et al. Colonoscopy and technetium-99 m white cell scan in children with suspected inflammatory bowel disease.  J Pediatr. 1999;  135 727-732
  PubMedGoogle Scholar
• 13 El Maghraoui A, Dougados M, Freneaux E, et al. Concordance between abdominal scintigraphy using technetium- 99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease.  Rheumatology (Oxford). 1999;  38 543-546
  CrossrefPubMedGoogle Scholar
• 14 Maconi G, Parente F, Porro Bianchi G. Hydrogen peroxide enhanced ultrasound-fistulography in the assessment of enterocutaneous fistulas complicating Crohn's disease.  Gut. 1999;  45 874-878
  CrossrefPubMedGoogle Scholar
• 15 Maconi G, Ardizzone S, Parente F, et al. Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis.  Scand J Gastroenterol. 1999;  34 1103-1107
  CrossrefPubMedGoogle Scholar
• 16 Soweid A, Chak A, Katz J, et al. Catheter probe-assisted endoluminal US in inflammatory bowel disease.  Gastrointest Endosc. 1999;  50 41-46
  PubMedGoogle Scholar
• 17 Yang S, Jung H, Kang G, et al. Appendiceal orifice inflammation as a skip lesion in ulcerative colitis: an analysis in relation to medical therapy and disease extent.  Gastrointest Endosc. 1999;  49 743-747
  CrossrefPubMedGoogle Scholar
• 18 Kim B, Barnett J, Kleer C, et al. Endoscopic and histological patchiness in treated ulcerative colitis.  Am J Gastroenterol. 1999;  94 3258-3262
  CrossrefPubMedGoogle Scholar
• 19 Moum B, Ekbom A, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis.  Am J Gastroenterol. 1999;  94 1564-1569
  CrossrefPubMedGoogle Scholar
• 20 Tanaka M, Saito H, Fukuda S, et al. Simple mucosal biopsy criteria differentiating among Crohn disease, ulcerative colitis, and other forms of colitis: measurement of validity.  Scand J Gastroenterol. 2000;  35 281-286
  CrossrefPubMedGoogle Scholar
• 21 Carbonnel F, Gargouri D, Lemann M, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis.  Aliment Pharmacol Ther. 2000;  14 273-279
  CrossrefPubMedGoogle Scholar
• 22 Bonner G, Petras R, Cheong D, et al. Short- and long-term follow-up of treatment for lymphocytic and collagenous colitis.  Inflamm Bowel Dis. 2000;  6 85-91
  PubMedGoogle Scholar
• 23 Wandall E, Damkier P, Moller Pedersen F, et al. Survival and incidence of colorectal cancer in patients with ulcerative colitis in Funen county diagnosed between 1973 and 1993.  Scand J Gastroenterol. 2000;  35 312-317
  CrossrefPubMedGoogle Scholar
• 24 Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study.  Aliment Pharmacol Ther. 2000;  14 145-153
  PubMedGoogle Scholar
• 25 Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis.  Am J Gastroenterol. 1999;  94 1643-1649
  CrossrefPubMedGoogle Scholar
• 26 Walsh S, Murphy M, Silverman M, et al. p27 expression in inflammatory bowel disease-associated neoplasia.  Am J Path. 1999;  155 1511-1518
  PubMedGoogle Scholar
• 27 Eaden J, Ward B, Mayberry J. How gastroenterologists screen for colonic cancer in ulcerative colitis: an analysis of performance.  Gastrointest Endosc. 2000;  51 123-128
  CrossrefPubMedGoogle Scholar
• 28 Rubin P, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps.  Gastroenterology. 1999;  117 1295-1300
  CrossrefPubMedGoogle Scholar
• 29 Engelsgjerd M, Farraye F, Odze R. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis.  Gastroenterology. 1999;  117 1288-1294
  CrossrefPubMedGoogle Scholar
• 30 Odze R. Adenomas and adenoma-like DALMs in chronic ulcerative colitis: a clinical, pathological, and molecular review.  Am J Gastroenterol. 1999;  94 1746-1750
  PubMedGoogle Scholar
• 31 Rubin P. Adenomas in ulcerative colitis: endoscopic polypectomy or colectomy?.  Inflamm Bowel Dis. 1999;  5 304-305
  PubMedGoogle Scholar
• 32 Petras R. The significance of “adenomas” in ulcerative colitis: deciding when a colectomy should be performed.  Inflamm Bowel Dis. 1999;  5 306-308
  PubMedGoogle Scholar
• 33 Delco F, Sonnenberg A. A decision analysis of surveillance for colorectal cancer in ulcerative colitis.  Gut. 2000;  46 500-506
  CrossrefPubMedGoogle Scholar
• 34 Hunt L, Eichenberger M, Petras R, et al. Use of a microsatellite marker in predicting dysplasia in ulcerative colitis.  Arch Surg. 2000;  135 582-585
  PubMedGoogle Scholar
• 35 Schramm C, Schirmacher P, Helmreich-Becker I, et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis: a case series.  Ann Intern Med. 1999;  131 943-946
  PubMedGoogle Scholar
• 36 Feagan B, Fedorak R, Irvine E, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease.  N Engl J Med. 2000;  342 1627-1632
  CrossrefPubMedGoogle Scholar
• 37 Egan L, Sandborn W, Tremaine W, et al. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis.  Aliment Pharmacol Ther. 1999;  13 1597-1604
  CrossrefPubMedGoogle Scholar
• 38 Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity.  Am J Gastroenterol. 2000;  95 1730-1734
  PubMedGoogle Scholar
• 39 Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.  Gastroenterology. 1999;  117 761-769
  CrossrefPubMedGoogle Scholar
• 40 Bell S, Kamm M. Review article: the clinical role of anti-TNF alpha antibody treatment in Crohn's disease.  Aliment Pharmacol Ther. 2000;  14 501-514
  CrossrefPubMedGoogle Scholar
• 41 Lochs H, Mayer M, Fleig W, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI.  Gastroenterology. 2000;  118 264-273
  CrossrefPubMedGoogle Scholar
• 42 D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine.  Gastrointest Endosc. 1999;  50 667-671
  PubMedGoogle Scholar
• 43 Dubinsky M, Lamothe S, Yang H, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.  Gastroenterology. 2000;  118 705-713
  CrossrefPubMedGoogle Scholar
• 44 Korelitz B, Mirsky F, Fleisher M, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine.  Am J Gastroenterol. 1999;  94 3248-3253
  CrossrefPubMedGoogle Scholar
• 45 Matsuhashi N, Nakajima A, Suzuki A, et al. Long-term outcome of non-surgical strictureplasty using metallic stents for intestinal strictures in Crohn's disease.  Gastrointest Endosc. 2000;  51 343-345
  CrossrefPubMedGoogle Scholar
• 46 O'Bichere A, Wilkinson K, Rumbles S, et al. Functional outcomes after restorative panproctocolectomy for ulcerative colitis decreases an otherwise enhanced quality of life.  Br J Surg. 2000;  87 802-807
  CrossrefPubMedGoogle Scholar
• 47 Brunel M, Penna C, Tiret E, et al. Restorative proctocolectomy for distal ulcerative colitis.  Gut. 1999;  45 542-545
  PubMedGoogle Scholar

D. Helper,M.D. 

Division of Gastroenterology
Indiana University Hospital
Room 2300

550 North University Boulevard
Indianapolis, IN 46202-5121
USA


Fax: Fax:+ 1-317-278-0164

Email: E-mail:dhelper@iupui.edu